Haldol Depot

Haldol Depot is a depot intramuscular injection containing the active ingredient haloperidol decanoate. It is supplied in an unspecified strength and is classified as a typical antipsychotic of the butyrophenone class. The formulation is intended for prescription use in the European market and is administered by healthcare professionals to manage psychotic conditions.

Haldol Depot is prescribed for the treatment of several psychotic disorders, particularly when long‑acting medication is preferred. It is used in both acute and maintenance phases of therapy.

- Schizophrenia, including chronic and relapsing forms. - Acute psychotic episodes requiring rapid symptom control. - Maintenance therapy for chronic psychosis to reduce relapse risk. - Adjunctive treatment when oral antipsychotics are not tolerated. - Situations where adherence to daily oral medication is challenging.

Side effects of Haldol Depot vary in frequency and severity. Patients should be monitored for both common and serious reactions.

Common: - Drowsiness or sedation. - Extrapyramidal symptoms such as tremor or rigidity. - Dry mouth and increased salivation. - Constipation or gastrointestinal discomfort.

Serious: - Neuroleptic malignant syndrome, a rare but life‑threatening condition. - Tardive dyskinesia, characterized by involuntary movements. - Severe hypotension or cardiac arrhythmias.

Before initiating Haldol Depot, clinicians should assess several safety considerations to minimize risks.

- Evaluate cardiovascular status, especially in patients with known heart disease. - Monitor for signs of extrapyramidal symptoms and tardive dyskinesia. - Use caution in patients with a history of seizures or neurologic disorders. - Assess liver and kidney function periodically. - Discuss potential pregnancy and lactation risks with women of childbearing age. - Ensure patients are educated about the injection schedule and possible side effects.

Haldol Depot may interact with other medications, affecting its efficacy or safety profile.

Avoid: - Concurrent use with other dopamine antagonists, which can increase extrapyramidal risk. - Strong CYP3A4 inhibitors that may raise haloperidol levels.

Use with caution: - CNS depressants such as benzodiazepines or alcohol, which may enhance sedation. - Anticholinergic agents that can mask extrapyramidal symptoms. - Medications that prolong QT interval, increasing cardiac risk. - Drugs affecting electrolyte balance, which may predispose to arrhythmias.